New pill aims to slow Alzheimer's in early stages
NCT ID NCT07252440
First seen Dec 24, 2025 · Last updated Jun 14, 2026 · Updated 33 times
Summary
This study tests an experimental tablet called TTYP01 in 180 people with early Alzheimer's (mild memory problems or mild dementia). Participants are randomly assigned to one of two doses of TTYP01 or a placebo. The main goal is to see if the drug slows decline in thinking and daily function over 78 weeks, and to check for side effects. This is a Phase 2 trial, meaning it is still early in testing for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Daping Hospital.
RECRUITINGChongqing, Chongqing Municipality, 400042, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.